References
1. Driggin E, Madhavan MV, Bikdeli B et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 Pandemic. Journal of the American College of Cardiology 2020;75:2352-2371.
2. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
3. Organization WH. WHO Director- General’s opening remarks at the media briefing on COVID-19—11 March 2020. WHO website: WHO, 2020.
4. Hassan A, Arora RC, Lother SA et al. Ramping up the delivery of cardiac surgery during the COVID-19 Pandemic: A Guidance Statement from the Canadian Society of Cardiac Surgeons. The Canadian Journal of Cardiology 2020.
5. Wong J, Goh QY, Tan Z et al. Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures in a large tertiary hospital in Singapore. Can J Anaesth 2020;67:732-745.
6. Organization WH. Infection prevention and control of epidemic- and pandemic-prone acute respiratory diseases in health care. WHO guidelines 2007. https://www.who.int/csr/bioriskreduction/infection_control/publication/en/. 2007.
7. Hassan A, Arora RC, Adams C et al. Cardiac surgery in Canada during the COVID-19 pandemic: A Guidance Statement from the Canadian Society of Cardiac Surgeons. The Canadian Journal of Cardiology 2020.
8. Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA 2020.
9. Liu K, Fang YY, Deng Y et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020;133:1025-1031.
10. Xu Z, Shi L, Wang Y et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-422.
11. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-1062.
12. Klok FA, Kruip M, van der Meer NJM et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020.
13. MacLaren G, Fisher D, Brodie D. Preparing for the most critically ill patients with COVID-19: The potential role of extracorporeal membrane oxygenation. JAMA 2020.
14. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz 2020;45:230-232.
15. Hong X, Xiong J, Feng Z, Shi Y. Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19? Int J Infect Dis 2020;94:78-80.
16. Bartlett RH, Ogino MT, Brodie D et al. Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure. ASAIO J 2020;66:472-474.
17. Namendys-Silva SA. ECMO for ARDS due to COVID-19. Heart Lung 2020.
18. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094-1099.
19. Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-271.
20. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72-73.
21. Lei S, Jiang F, Su W et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine 2020:100331.